Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Gross Profit (2016 - 2018)

Historic Gross Profit for Theravance Biopharma (TBPH) over the last 6 years, with Q1 2018 value amounting to $7.5 million.

  • Theravance Biopharma's Gross Profit rose 19710.55% to $7.5 million in Q1 2018 from the same period last year, while for Mar 2018 it was $14.3 million, marking a year-over-year decrease of 5324.7%. This contributed to the annual value of $9.4 million for FY2017, which is 2271.6% down from last year.
  • As of Q1 2018, Theravance Biopharma's Gross Profit stood at $7.5 million, which was up 19710.55% from $1.4 million recorded in Q4 2017.
  • In the past 5 years, Theravance Biopharma's Gross Profit registered a high of $20.0 million during Q1 2015, and its lowest value of -$1.8 million during Q4 2014.
  • Its 5-year average for Gross Profit is $6.3 million, with a median of $4.5 million in 2016.
  • Over the last 5 years, Theravance Biopharma's Gross Profit had its largest YoY gain of 5380000.0% in 2014, and its largest YoY loss of 112228.57% in 2014.
  • Theravance Biopharma's Gross Profit (Quarter) stood at -$1.8 million in 2014, then surged by 138.68% to $692000.0 in 2015, then surged by 556.94% to $4.5 million in 2016, then tumbled by 69.23% to $1.4 million in 2017, then skyrocketed by 435.6% to $7.5 million in 2018.
  • Its Gross Profit stands at $7.5 million for Q1 2018, versus $1.4 million for Q4 2017 and $3.3 million for Q3 2017.